Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

S Umemura; G Sakamoto; H Sasano; H Tsuda; F Akiyama; M Kurosumi; Y Tokuda; T Watanabe; M Toi; T Hasegawa; R Y Osamura

doi:10.1007/BF02967531

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

Breast Cancer. 2001;8(4):316-20. doi: 10.1007/BF02967531.

Authors

S Umemura¹, G Sakamoto, H Sasano, H Tsuda, F Akiyama, M Kurosumi, Y Tokuda, T Watanabe, M Toi, T Hasegawa, R Y Osamura

Affiliation

¹ Department of Pathology, Tokai University School of Medicine, Isehara, 259-1193, Japan.

PMID: 11791124
DOI: 10.1007/BF02967531

Abstract

For the treatment of patients with metastatic breast cancer by humanized anti- human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. "A guideline for HER2 testing" and "HER2 atlas" produced by the "Pathological committee for optimal use of trastuzumab" are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Biopsy, Needle
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Breast Neoplasms / pathology*
Female
Genes, erbB-2 / genetics*
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Neoplasm Metastasis
Neoplasm Staging
Practice Guidelines as Topic
Receptor, ErbB-2 / analysis*
Sensitivity and Specificity
Trastuzumab
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Receptor, ErbB-2
Trastuzumab